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Abstract
Background: Traditional medication adherence measures do not account for the pharmacokinetic (PK) properties of the
drugs, potentially misrepresenting true therapeutic exposure.
Methods: In a population of HIV-infected Kenyan children on antiretroviral therapy including nevirapine (NVP), we used a
one-compartment model with previously established PK parameters and Medication Event Monitoring Systems (MEMS®)-
recorded dosing times to estimate the mean plasma concentration of NVP (Cp) in individual patients during 1 month of
follow-up. Intended NVP concentration (Cp’) was calculated under a perfectly followed dosing regimen and frequency. The
ratio between the two (R = Cp/Cp’) characterized the patient’s NVP exposure as compared to intended level. Smaller R values
indicated poorer adherence. We validated R by evaluating its association with MEMS®-defined adherence, CD4%, and spot-
check NVP plasma concentrations assessed at 1 month.
Results: In data from 152 children (82 female), children were mean age 7.7 years (range 1.5–14.9) and on NVP an average of
2.2 years. Mean MEMS® adherence was 79%. The mean value of R was 1.11 (SD 0.37). R was positively associated with
MEMS® adherence (p < 0.0001), and lower-than-median R values were significantly associated with lower NVP drug
concentrations (p = 0.0018) and lower CD4% (p = 0.0178), confirming a smaller R value showed poorer adherence.
Conclusion: The proposed adherence measures, R, captured patient drug-taking behaviours and PK properties.
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Introduction
Adherence to antiretroviral therapy (ART) is an essential
component of successful management of HIV/AIDS [1].
Studies have consistently shown strong associations
between poor ART adherence and adverse clinical out-
comes, including patient mortality [2], disease progression
as measured by CD4 cell counts [3,4] and viral load [5–7],
and development of drug resistance [8,9]. Despite mount-
ing evidence on the benefit of ART adherence, suboptimal
patient adherence remains common in adults and in chil-
dren [10,11]. In addition, accurate and objective measure-
ment of ART exposure, particularly for children in resource-
limited settings (RLS), remains a challenge as adherence
studies have used different adherence assessment methods
and reported inconsistent findings [12].
A direct consequence of poor ART adherence is the
lower-than-intended level of therapeutic exposure.
Traditional medication adherence measures, such as
patient self-reports, while easy to obtain, do not always
have good concordance to actual adherence levels or clin-
ical outcomes [13–15]. While measures like pharmacy refill
records have performed better in some studies, their valid-
ity among children in RLS has been under-explored [16,17].
Moreover, most studies on adherence in resource-limited
studies have not incorporated plasma drug concentrations
and thus actual levels of exposure to ART has not been
evaluated. Electronic dose monitors like Medication Event
Monitoring Systems (MEMS®, MWV/AARDEX Inc.,
Switzerland) record the precise timing of medication bottle
openings and thus may provide a more accurate record of a
patient’s dosing events and medication taking behaviour.
Indeed, ART adherence measures based on MEMS®, typi-
cally calculated as the ratio of bottle openings (i.e., “doses
taken”) and the total number of doses prescribed for a
given time period, are more strongly correlated with HIV
virologic responses compared with other measures [15].
Still, the existing MEMS adherence measures do not
account for the pharmacokinetic (PK) properties of the
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drugs and thus do not reflect patients’ true therapeutic
exposure. It is generally understood that the PK properties
of a medication can significantly affect the therapeutic out-
come [18]. For example, drugs with longer half-lives tend
be more forgiving of occasional dose omissions and also
more tolerant of variations in dosing time [19].
The objective of the current research is to develop a new
adherence measure that combines the recorded MEMS®
dosing times with established PK parameters of Nevirapine
(NVP) for quantification of patients’ NVP exposure. We
approximated actual NVP exposure and compared it to the
intended level of exposure in individual patients, potentially
enhancing the extent to which MEMS® data can be used to
understand whether patients reach therapeutic exposure
levels. This is an approach that we have previously used to
investigate patients’ adherence to beta-adrenergic antago-
nist metoprolol [20]. In the present study, we constructed a
similar PK-based measure for quantification of patient adher-
ence to NVP in cohort of HIV-infected Kenyan children.
Methods
Study design
This study is part of an ongoing investigation aimed at devel-
oping medication adherence assessment tools for HIV-
infected Kenyan children. The study protocol has been
described previously [21,22]. Briefly, HIV-infected children
<14 years of age on first-line paediatric ART regimens who
attended a large paediatric HIV clinic of the Academic Model
Providing Access to Healthcare (AMPATH) in Eldoret, Kenya
were followed prospectively with monthly clinical visits at
which time various adherence assessments were adminis-
tered. Informed consent was obtained from eligible partici-
pants and their caregivers prior to study enrolment. The study
protocol was approved by the Institutional Review Board of
Indiana University School of Medicine in Indianapolis, Indiana,
and by the Institutional Research Ethics Committee at Moi
University School of Medicine in Eldoret Kenya.
Clinical assessment
At baseline, patients received clinical examination. Basic
demographic and relevant clinical information was ascer-
tained. As part of the study protocol, patients received NVP
in MEMS® electronic dose monitors that created time stamps
for all bottle openings. Patients were informed of the purpose
ofMEMS® and instructed in care of the cap and bottle. Dosing
time data recorded by the MEMS® were read into PowerView
software (Version 3.5.2; AARDEX, Inc.) and then converted
into a SAS dataset for further analysis (Version 9.4; SAS
Institute, Inc., Cary North Carolina). Adherence based on
MEMS® bottle openings were calculated as a percentage
using the number of doses taken (i.e., bottle openings) divided
by the number of doses prescribed. A two-hour window was
used to calculate doses taken – i.e., repeated openings within
2 h from the initial opening were not counted. This research
was based on MEMS® data collected after 1 month of follow
up. At 1 month of follow up, blood samples were collected
from all patients for CD4 cell percentage (CD4%) and NVP drug
concentration levels.
Construction of PK-based medication adherence measures
We constructed ART adherence measures by estimating
and contrasting the patient’s plasma concentration of NVP
(Cp) to its intended levels (Cp’). We measured the ratio, or
proportion, of intended therapeutic level achieved (R = Cp/
Cp’). In this research, we approximated the hourly NVP
concentrations via an iterative algorithm by a one-compart-
ment model with MEMS®-recorded dosing times and pre-
viously established PK parameters [23].
The calculation was carried out with an iterative algo-
rithm based on the standard 1-compartment model
Cp i; t½  ¼ F  d i; t½   ka
V i½  ka  keð Þ exp ke  tð Þ  exp ka  tð Þ½ ;
where Cp i; t½  is the ith subject’s NVP concentration at time
t, d i; t½  is the subject-specific dose level at time t, V i½  is the
volume of distribution, and F is the bioavailability of NVP. In
the current study, we used F ¼ 0:93, and ka ¼ 0:23/h,
andke ¼ 0:0614/h. Dose d i; t½  was determined based on
the child’s age and weight [24]. With multiple dosing, we
calculated the NVP concentration of a given subject at hourly
interval. An iteratively algorithm was used to take into con-
sideration of the cumulative effects of repeated dosing.
Details of the algorithm were presented in the Appendix.
The mean NVP concentration (Cp) was obtained by aver-
aging the hourly NVP levels. Similarly, we calculated Cp’ by
using the same PK parameters under the ideal medication
taking behaviour (i.e., no missed doses and perfectly spaced
dosing time). Specifically, we expressed the plasma concen-
tration of NVP exposure for the ith patient at tth hour as
Cp i; t½ , where i ¼ 1; 2;    ; n, and t ¼ 0; 1; 2;    ; Ji,. Using a
one-compartment model under a given set of PK para-
meters, we calculated Cp i; t½  through an iterative algorithm,
which incorporates the cumulative drug concentrations from
previous doses taken based on the patient’s MEMS® records
[20]. We calculated the intended NVP concentration for ith
patient at tth hour as Cp0 i; t½  in a similar fashion, under the
perfect dosing times. The estimated NVP levels (Cp i; t½ )
were graphically presented and visually compared to the
intended NVP levels (Cp0 i; t½ ) over time. To illustrate, data
from 4 patients are presented in Figure 1.
Averaging the hourly drug concentration levels Cp i; t½ 
and Cp0 i; t½ , we obtained the estimated mean NVP levels
under the observed dosing times, Cpi ¼ ð
Pt¼0
Ji
Cp i; t½ Þ=Ji and
intended dosing times, Cp0i ¼ ð
PJi
t¼0
Cp0 i; t½ Þ=Ji. We proposed
to use Ri ¼ min CpiCp0 i ; 1
h i
to characterize the patient’s level
of medication adherence. Intuitively, Δi represented the
average amount of the patient’s deviation from the
intended plasma NVP concentration, whereas Ri was the
proportion of intended NVP concentration achieved under
the recorded dose taking behaviour. The ratio CpiCp0 i could
exceed 1 if a patient opened the MEMS® lid more often
than supposed to. To prevent spurious interpretation of Ri
value great than 1, we capped Ri at 1.
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It should be noted that the population PK parameters were
unable to fully account for the observed between-subject
variation. Factors at the patient level, such as route of admin-
istration, drug binding and local metabolism, characteristics
of absorbing surfaces, and gastroenterological conditions
may well affect the absorption and elimination of the drug.
But introduction of patient-specific PK parameters would
greatly reduce the practical utility of the proposed adherence
measure, and thus defeating the purpose of the research.
This said, the use of subject-specific volume distribution, dose
level, and dosing times helps to accommodate, at least in
part, the large variability that might exist across subjects.
Finally, we noted that the estimation of NVP concentration
at hourly intervals was proportional, and differed from the
area under the fitted drug concentration curve (AUC) by a
constant. The proposed measure, therefore, could be viewed
as an effort to quantify drug exposure by comparing the AUCs
under the intended and actually recorded dosing times.
Measurement validation
We validated the proposed measure Ri by evaluating its
association with our primary end point, MEMS®-defined
adherence, as well as to secondary end points CD4% and
spot-check NVP plasma concentrations, all assessed at
1 month of follow up. Given the delayed impact of adher-
ence on CD4%, we also validated the proposed measure
against CD4% taken at 4 months of follow up (results not
presented and were sufficiently similar to results at 1 month
of follow up). Additionally, we calculated the correlation
between the PK-based measure (RiÞ and compared the
meanR levels in patients with ≥90% and <90% MEMS®
adherence. We then assessed R’s association with the spot-
check NVP concentrations as well as CD4% using regression
analyses. We dichotomized the calculated R values at the
sample median, and compared the spot check NVP concen-
tration levels and mean CD4% values between those who
have lower-than-median and higher-than-median R values,
with these analyses being adjusted for age, sex, and ART
duration. All analyses were performed using SAS software
(Version 9.4, SAS Institute, Inc., Cary, North Carolina). P-
values less than 0.05 were considered statistically significant.
Results
Demographic and clinical characteristics
We analyzed data from 152 children (82 female).
Demographic and clinical characteristics of the study
patients at baseline are presented in Table 1. At enrolment,
mean age of the study patients was 7.7 years (standard
deviation, SD = 3.2). Subjects were on NVP for an average
of 2.2 years (SD 1.8 years). Children had moderate-to-
severe clinical disease (57.8% were at WHO Stages 3 or 4)
with mean CD4% of 27% at the study entry. At the 1 month
follow-up visit, the subjects had an average MEMS® adher-
ence of 79% (SD 26%), a mean CD4% of 27.6% (SD 10.2%),
Figure 1. Observed versus optimal plasma concentrations using the PK-based measure in 4 paediatric patients.
Curves plotted on graph with NVP drug concentration (y-axis) and time (x-axis). Observed (dotted line) versus intended (solid line) NVP
plasma concentration curves are shown for 4 paediatric patients (clockwise from top left, patient A, B, C, D) with varying levels of adherence:
A has good adherence (R = 1.066), B has fair adherence (R = 0.743), C has poorer adherence (R = 0.620), and D has very poor adherence
(R = 0.565) (Seven days of data shown.).
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and a mean NVP concentration of 9.45 mg/L (SD 6.94 mg/L)
(Table 2).
The estimated and intended NVP exposure levels are
presented in Table 2. Specifically, the mean values Cp,
Cp’, and R value were 3.10 mg/L (SD 1.34 mg/L), 2.83 mg/
L (SD 0.62 mg/L), and 1.11 (SD 0.37), respectively. The
mean ratio of greater than 1 indicated that on average,
the subjects in the study cohort adhered well to their
prescribed medicine; some subjects had in fact opened
their medication containers slightly more frequently than
expected. Among all of the hourly estimated values of NVP
concentration from all subject, approximately 45% were
above the trough level of 3 mg/L.
Validation of the PK-based adherence measures
Before validating the proposed adherence measures, we
examined the estimated NVP concentration levels overtime
in study subjects (data not shown). As illustrated by the
four selected cases in Figure 1, the magnitude of Ri was
strongly related to the MEMS® bottle opening patterns.
While occasional omission of a dose did little to impact
Ri, more systematic skipping of NVP doses resulted in
significantly reduced Ri levels.
The ratio R was positively associated with MEMS® adher-
ence (Figure 2(b); γ ¼ 0:530; p<0:0001Þ. Patients with
lower-than-median R values had significantly lower NVP
concentration than those who had higher-than-median R
values (Figure 2(c), 7.546 vs. 9.835 mg/L; p = 0.0090), as
measured in the spot-check samples. Patients with lower-
than-median R values also had significantly lower CD4%
(Figure 2(d); 25.97% vs. 29.29%; p = 0.0447). Correlation
analysis also confirmed that a lower R value was also
associated with lower spot-check plasma concentration
(p < 0.0001), but R’s association with CD4% did not reach
the level of statistical significance (p = 0.2718).
These findings confirmed our hypothesis that a smaller R
value was associated with non-adherence, as measured by
both MEMS® adherence and by spot-check NVP concentra-
tion; they were also associated with significantly reduced
CD4% in study subjects.
Discussion
In this research, we proposed and validated a novel PK-
based measures for NVP adherence in Kenyan children. The
proposed measure, R, differs from existing adherence mea-
sures (e.g., MEMS® monitoring alone) in its ability to
accommodate the PK properties of the drug, and to char-
acterize patient adherence by comparing the estimated
drug exposure under MEMS-recorded dosing times to that
obtained under the perfectly followed dosing times. In
other words, our measure accounted not only for patient’s
drug taking behaviour but also the properties of the drug,
which makes it a more clinically useful measure of adher-
ence to medication. While patient’s drug-taking behaviour
Table 1. Demographic and clinical characteristics of the
study subjects
Cohort Characteristics
N = 152
Mean (standard deviation)
or Frequency (%)
Child Characteristics
Mean age, years 7.7 (3.2)
Female 82 (56%)
Mean weight-for-age z score −1.5 (1.2)*
Mean ART duration, years 2.2 (1.8)
Mean CD4% 27% (10%)
WHO stage
1 30 (20%)
2 30 (20%)
3 75 (51%)
4 10 (7%)
Not answered 2 (1%)
Caregiver and/or Family Characteristics
Caregiver relationship to child
Mother 98 (67%)
Father 14 (10%)
Sibling 1 (1%)
Grandparent 7 (5%)
Non-relative 6 (4%)
Other 21 (14%)
Individuals who give the child
ART**
Mother 126 (83%)
Father 50 (33%)
Sibling 64 (42%)
Other relative 63 (42%)
Child took own 43 (28%)
Caregiver employed outside the
home
119 (81%)
Enrolled in AMPATH nutrition
program
25 (17%)
Food insecurity (reported “not
enough food for family”)
100 (68%)
Reported difficulty with
transportation to clinic
121 (82%)
*Weight-for-age Z scores based on World Health Organization Child
Growth Standards
**More than one individual could be selected as giving ART to child
Table 2. Medication adherence and clinical outcome at one
month (means and standard deviations)
MEMS® (% doses taken) 78.91 (26.43)
CD4% 27.65 (10.19)
NVP Spot Check 9.45 mg/L (6.94)
Cp 3.10 mg/L (1.43)
Cp’ 2.83 mg/L (0.62)
R 1.11 (0.37)
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is a major contributor to the therapeutic exposure, beha-
viour alone does not solely determine the level of expo-
sure. The accommodation of the PK properties of the drug
incorporates a previously unaccounted factor into consid-
eration. In addition, with the iterative algorithm for Cp0i and
Cpi, occasional dose omission and systematic dosing time
shifting were appropriately incorporated into the calcula-
tion. In a sense, Cp0i and Cpi could be viewed as approx-
imation of the area under the drug concentration curves
under the ideal and actual dosing times. In this regard, the
standard MEMS® adherence measure ignores the effect of
actual dosing times, and thus under-utilized collected dos-
ing event data. Together, the measure offered an appealing
set of characteristics that made it suitable for monitoring
NVP adherence and exposure simultaneously – even when
one does not have access to drug concentration data. While
these measures require established PK drug parameters
and precise dose timing records, they may offer great
potential for controlled trials and drug studies that require
more accurate drug exposure estimates over prolonged
periods of time.
There are several unique advantages to R. The measure,
R, which represents the average percentage of drug levels
achieved by the patent, is a unitless measure because it is
based on the intended and actual drug levels. While the
calculation of R requires PK parameters, the adherence
measure, R, as a ratio of intended and actual is unitless
and thus not drug specific. In addition to being easy to
interpret, the measure, R, could be used to comparatively
assess adherence levels across patients with varying drug
doses and also across drugs. In most clinical settings, we
contend, R is likely to be a practical measure to use. In our
findings here, R values were somewhat greater than MEMS-
measured adherence, suggesting that NVP is not hugely
sensitive to dose timing.
This study has a number of important limitations to
consider. First, as noted earlier, one of the major limita-
tions of R as an adherence measure is that it requires
established population PK parameters. As a result, the
estimated concentration curves will not fully account for
the between subject variations. To some extent, the use of
subject-specific doses and the precisely recorded dosing
times might help to better accommodate the potentially
large variability in drug concentration, as drug absorption
and elimination are known to be related to local condi-
tions of drug metabolism. But for children in a RLS, parti-
cularly in sub-Saharan Africa, there are few PK data for
major antiretroviral drugs, introducing subject-specific PK
parameters, or treating them as functions of observed
patient factors would greatly increase the difficulty of
computation, severely limit the potential for the practical
use of the proposed measure. The reliance on PK data also
restricts the measures’ generalizability. In addition, dose-
timing technology remains relatively expensive although
there are reasons to believe that the cost of MEMS® could
substantially decrease in the coming years given the sus-
tained interest in implementing adherence technologies
for routine clinical use. For the same reason, we did not
consider drug-to-drug interactions in the current study;
those interactions may affect the metabolism of the
NVP. Second, the current research could not validate R
against carefully assessed viral loads or viral resistance
patterns, which are generally viewed as the most signifi-
cant clinical endpoints for adherence to ART but are rou-
tinely not available in RLS such as western Kenya. We tried
to overcome this limitation by validating our adherence
measure against three available end points (MEMS®,
CD4%, and spot-check drug concentration), which
revealed consistent results of the measures’ validity.
Finally, we relied on MEMS® for records of dosing time,
but of course we could not be sure that the patient did
actually take the medicine each time he/she opened the
MEMS® bottle (and vice versa, we did not know if they
took out more than one dose). In previous work, we have
shown high correlation between MEMS® adherence and
CD4% and spot-check drug concentrations, as well as
caregiver-reported missed doses, suggesting that MEMS®
reflects actual drug taking behaviour in this cohort [21].
Notwithstanding these limitations, we contend that the
measure described in this paper represent a novel attempt
to more objectively quantify the patients’ exposure to a
prescribed therapeutic agent and provides a methodology
that should be tested through more rigorous evaluation
that includes viral load and genotypic resistance testing.
Figure 2. (a) Scatter plot of MEMS vs. R (left panel); (b) Spot check NVP concentration by R median categories (middle); (c) CD4% by R
median categories (right).
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Conclusions
We created and validated a novel adherence measure that
accommodates the PK properties of the drug and medica-
tion taking behaviours. This measure offers key advantages
to traditional medication adherence measures, particularly
in research settings where more precisely measured drug
exposure is needed but direct assessment is not feasible.
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